Clinical research when performed as per the existing guidelines is a highly exhaustive, rigorous, focussed and time-consuming job. The preparatory part of research involves raising the research question, submitting the research proposal to authorities, obtaining relevant permissions from various regulatory bodies and conduct of the trial. This is logically followed by submission of all of the research findings for publication in peer-reviewed journals.
The results of the research that get published are expected to be replicable by others. This depends on its precision in terms of the methodology including the sample size; the results extrapolated from the study should also be applicable to the larger population so that the observed effects are near identical to true effects. Strong statistical correlations are expected to be discussed minimising bias and confounding.
During the process, all the research questions raised may not be answered as per the plan due to inadequate methodology or its poor execution. Sometimes, completed research is not submitted for publication or is only presented initially as abstract in scientific meetings or presented only as a paper later. The research is thus 'wasted' as the outcomes are not brought out to the public domain at all. More than 60% of the studies are not submitted for publication, and this figure has remained so around this level for the last few years. [1] This failure to publish research ('file drawer effect') is because the researcher feels that the outcomes were not positive and/or because they were statistically insignificant. [2] This constitutes a large publication bias and one of the major factors contributing to poor replicability of research findings. The common reason reported for failure to publish the findings as full-length articles by the authors is lack of time and is unrelated to the journal policy and review process. [1, 3] Missing data in published clinical trials, unintentional or deliberate ('dissemination bias'), are other sources leading to improper conclusions and may contribute to improper and insufficient outcome assessments in related meta-analyses. Fallacies in the choice of randomised trials by the authors of the meta-analyses themselves can be a source of poor analysis of evidence, thus depriving the clinicians, the patients, the policy-makers and the funding agencies of the best current evidence related to benefits and harms of an intervention. In a review designed to check the extent to which meta-analyses of drugs and biologics focus on specific named agents or even only a single agent, and identify characteristics associated with such focus, it was found that 81% did not include all treatments and 43% covered only specific treatments. [4] Selective removal of data and selective removal of patients ('data massaging') can be worse than non-reporting of all outcomes. [5] Efforts have been made and suggestions provided by an expert group in the form of evidence-informed general and targeted recommendations so that the bias related to dissemination is reduced, addressing all the stakeholders. [6] The Overcome failure to Publish nEgative fiNdings project is a European Commission initiative with the agenda to identify dissemination bias and to develop recommendations to overcome incomplete or selective access to trial results, starting with the definition of a clinical trial. One of the strong recommendations is to promote trial registration and posting of the results in the registry and support initiatives to facilitate searches across multiple trial registries. Deadlines for posting the results from aggregate data after completion of research will go a long way in reducing the dissemination bias, avoiding the likelihood of missing data. A recent joint statement by the Indian Council of Medical Research and other bodies across the world (the UK Medical Research Council, the Norwegian Research Council, the Bill and Melinda Gates Foundation, etc.) agreed to enforce within next 12 months, the policy of compulsorily ensuring registration of trials funded or sponsored by them and the results to be disclosed within a time frame (1 year) on the registry and/or as publication in journals. [7] Compliance rate by the researchers unfortunately is only one in five. [8] A new online tool the TrialsTracker identifies completed trials from clinicaltrials.gov, searches for results in the registry and on PubMed and presents summary statistics for each sponsor online. Sponsors who fail to make the results available online are tracked. This service is aimed to reduce withholding of trial results and promote transparency in research process. [9] The recommendation on prospective trial registrations is very much necessary in countries such as India. Trial registration in the Clinical Trials Registry-India [10] has been made mandatory by the Drugs Controller General (India) (www.cdsco.nic.in) since 15 th June 2009.
Many journals have also insisted on trial registration as a pre-requisite for publication. The Indian Journal of Anaesthesia (IJA) is encouraging trial registration for the past few years and hopefully, and rightly, registrations would likely be made mandatory in the near future. By this, the IJA hopes to reduce the dissemination bias in Indian scenario, and also enhance the stress on rigorous methodology.
Many meta-analyses and systematic reviews restrict the inclusion criteria deliberately so as to focus on specific cause-effect relationships, filtering out many inconvenient but significant criteria. Individual participant data are very valuable during the analysis but are not be available for review in many trials, adding to the bias as they may not be reflected in the evidence base. [11] Outcomes and participant data published only in grey literature miss out analysis by some researchers, thus leading to misinterpretation of the final results and outcomes. In one of the surveys involving 31 meta-analyses to identify publication bias, [11] it was found that about 70% of the articles did not extract individual participant data from the grey literature.
Transparency of analysis by the authors of meta-analyses will promote more objective and safe end-point for the readers and clinicians. An interesting fact emerges from a meta-analysis, assessing the differences in methodological quality and conclusions of industry-supported meta-analyses versus 'non-profit' or 'no support' meta-analyses. Out of the 39 meta-analyses, ten had industry support, 18 non-profit or no support and 11 undeclared support. In the non-profit or no support groups, there was less bias in the selection of studies and search methods were more clearly defined; blinding and allocation concealment, exclusion of patients and studies was also clearly mentioned, as compared to industry-supported meta-analyses. The industry-supported meta-analyses were twice more likely to recommend the drug as compared to the meta-analyses with no-profit or no support (40% vs. 22%). [12] The transparency may thus be better maintained in the non-support group as compared to industry-supported group and results and inferences better accepted by the clinician.
Many systematic reviews fail to reveal all the evidence and all the research outcomes available. They are built with a narrow scope, withholding information about alternative evidence. [1] Considering the larger picture, this bypass of significant outcomes and evidence does not benefit the patient or the clinician. [13] Many reviews appear out-dated due to rapid developments in the field by the time they are published. It is also difficult for authors to update and publish them due to time and financial constraints. One way to overcome this limitation is automation of the whole-trial search and selection process, as much as possible. [13] Systematic review with live cumulative network meta-analysis can allow for examining the totality of the randomised evidence using trial networks as the conventional meta-analyses have a narrow focus. [13] How to minimise the dissemination bias and file drawer effect?: Journals should modify their policies and instructions so that greater value is provided to soundness of design and analysis, completeness of data, inclusion-exclusion criteria, etc. rather than the 'positive' results. Encouragingly, some journals have appeared purely to promote negative results and with open/transparent review (removing anonymity of reviewers), without publication bias, publishing submissions only on scientific validity without looking for positive outcomes. Other ways by which trials with negative results and statistically insignificant results can be published could be to have the journal explicitly state that the journal cares about the genuineness of the research and allows presentation of all of data including negative ones. [14] It is also suggested that publication bias from the editors and referees of a journal, which is an inherent possibility, can be overcome by monitoring by an associate editor or publisher.
Defences towards the selective publications approach exist; the data thereof are scientifically rich and lesser number of such trials are required to create a near-perfect meta-analytic estimation of the true effect. [2] Thus, the file drawer effect, with 'withheld' publications, is claimed to be beneficial in conveying the best information and outcomes. It is also suggested that repeat submissions of scientific articles can be more strong in terms of statistical strengths and avoiding bias. [2] The larger emerging picture nudges us to celebrate negativity for its great worth in research. Let us strive to unhide the hidden files. Confirmed 'nullness' after null hypothesis has significant implications in research analysis. 
